Perhaps caught up is the wrong way to term it, however clearly it is not he case that the Lecanumab result would be a good one from the delayed start analysis as it would indicate the participants didn't need to take the drug in the first 18 months of the trial, they could have taken a placebo instead for 18 months and then the drug and almost ended up with same result another 18 months later (3 years in total).
Of course it would appear in this time they beat ADNI over 3 years, however if beating this measure was what mattered (instead of beating placebo) then Blarca would be approved for treating RETT now as Blarca clearly beat ADNI for RETT in the excellence trial.
However it would appear we cannot say the dosed group in Blarca trial would have been just as well off taking placebo for 48 weeks then going onto drug because the former placebo group continue deteriorating even worse than the former dosed group.
Market Data 
Markets 
AI
